Cancer BiologybioRxivPreprint
Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancers
Lindsey N Aubuchon, Deanna H. Wong, Natasha Ramakrishnan…·Priyanka Verma
This study shows that targeting ALC1 can enhance PARP inhibitor effectiveness in ovarian cancers, particularly in HRD and CCNE1-amplified tumors, with minimal toxicity.
DOI 10.64898/2025.12.04.692458